Castle Biosciences Inc. (CSTL), a molecular diagnostics company, which reported a 74% increase in revenue for the second quarter of 2024, has once again raised its guidance for the year.
The company offers tests for skin cancers, Barrett's esophagus, mental health conditions and uveal melanoma. DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher Barrett's Esophagus Assay and IDgenetix, a cheek swab test to guide medication management for patients' neuropsychiatric conditions, such as depression and anxiety, are the company's commercially available tests.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com